Dr. Michael Javaheri , MD
Ophthalmology - Retina Specialist • Beverly Hills, CA
9735 Wilshire Blvd Ste 219
Beverly Hills, CA 902122110
This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.
-
Dr. Michael Javaheri is listed in NPPES under Ophthalmology - Retina Specialist.
-
NPI assigned on February 29, 2008; this date does not establish years in practice.
-
Published CMS data list 61,984 Original Medicare Part B services in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Published rows only; this is not a quality measure.
-
Published Part B service records, 2024:
- J2777 — Injection, faricimab-svoa, 0.1 mg: 45,541 service units.
- 92134 — Imaging of retina: 3,327 service units.
- J2781 — Injection, pegcetacoplan, intravitreal, 1 mg: 2,295 service units.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Units differ by code; these are not visits or a measure of quality.
CPT® only copyright 2023 American Medical Association. All rights reserved. Service names are shortened from CPT Consumer Friendly Descriptors (CMS data, 2024). CPT notice
See all 27 records in the table · Guide: How to read Medicare Part B data
-
Published CMS data list 384 Medicare Part D prescriptions, including refills, in 2024.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Published rows only; this is not a quality measure.
-
Published Part D records, 2024:
- Prolensa (Bromfenac Sodium) — 99 prescription fills, including refills.
- Prednisolone Acetate — 70 prescription fills, including refills.
- Bromfenac Sodium — 40 prescription fills, including refills.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024. Drug names come from pharmacy claims. Listing a drug here is not an endorsement or a recommendation.
See all 13 records in the table · Guide: How to read Medicare Part D prescriber data
-
More Medicare Part B services than 90% of clinicians listed under Ophthalmology - Retina Specialist in California (2024, 180 clinicians with data). Median for this group: 10,375. Middle half: 3,212 to 33,038.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024. Billing and prescribing volume is not a quality rating.
-
Medicare Part B services went from 6,019 in 2020 to 61,984 in 2024.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2020–2024.
Practice Location & Contact Primary Location
9735 Wilshire Blvd Ste 219
Beverly Hills, CA 902122110
CMS Doctors and Clinicians lists 1 group name: Cha Medical And Surgical Group Pc. See the list
Source: CMS Doctors and Clinicians National Downloadable File, CMS release of October 2, 2026.
Listings do not confirm current availability, employment or a shared ownership network.
Medicare Profile & Education
Source: CMS Doctors and Clinicians National Downloadable File, CMS release of October 2, 2026
2003
What Public CMS Data Show
Ophthalmology - Retina Specialist: NPPES taxonomy is a reported classification, not proof of board certification.
Medicare patients
1,001 people with Original Medicare in 2024
It gives a sense of how many people with Medicare this clinician treated that year.
Source: CMS, Medicare Physician & Other Practitioners – by Provider, 2024.
Medicare-allowed amount
About $5,353,947 in 2024
The total amount Medicare approved for these services in 2024. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.
It shows the total cost of this clinician's Original Medicare services under Medicare's fee rules.
What this does not show: Medicare-allowed amount
This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
Paid by Medicare
About $4,226,163 in 2024
The part of the Medicare-allowed amount that Medicare itself paid in 2024, after patients' deductibles and coinsurance.
The gap between the allowed amount and this number is roughly what patients and their other insurance paid.
What this does not show: Paid by Medicare
This is not the clinician's income and not a measure of quality.
Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.
30-day fills
505 standardized 30-day fills in 2024
CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.
What this does not show: 30-day fills
It is not a count of patients and not a measure of quality.
Part D drug cost
$76,925 in 2024
The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.
It shows the total spending on drugs this clinician prescribed, not what any one patient paid.
What this does not show: Part D drug cost
A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.
Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024.
Open Payments general payments, program year 2025
All general payments: $127,930.91 across 136 records.
By nature of payment (3 largest of 5)
- Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program: $66,550.96 across 14 records.
- Consulting Fee: $33,370.00 across 10 records.
- Compensation for serving as faculty or as a speaker for a medical education program: $15,840.00 across 5 records.
Reporting-company totals (3 largest of 11)
- Regeneron Pharmaceuticals, Inc.: $109,134.00 across 80 records.
- Apellis Pharmaceuticals, Inc.: $17,138.43 across 20 records.
- Tarsus Pharmaceuticals, Inc.: $311.33 across 5 records.
Research and ownership records are not included in these totals; they are in the table below.
A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.
Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).
Years since graduation
23 years (graduated 2003)
CMS Doctors and Clinicians data list 2003 as the year this clinician finished professional school.
It tells you roughly how long ago the clinician finished school.
What this does not show: Years since graduation
It is not the number of years in practice, and more years does not mean better care.
Source: CMS Doctors and Clinicians National Downloadable File, CMS release of October 2, 2026.
NPI first issued
2008
The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.
What this does not show: NPI first issued
NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.
Source: CMS NPPES NPI Registry.
Accepts Medicare assignment
CMS data list this clinician as accepting Medicare assignment. This means agreeing to take the Medicare-approved amount as full payment for covered services.
With Original Medicare, you usually pay only your deductible and coinsurance, and the office sends the claim to Medicare for you.
Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.
Source: CMS Doctors and Clinicians, CMS release of October 2, 2026; Medicare.gov, “Does your provider accept Medicare as full payment?”
No telehealth indicator
CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.
Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians, CMS release of October 2, 2026.
Enrolled in Medicare (PECOS)
Dr. Javaheri has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.
It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Can order Medicare-covered services
CMS lists Dr. Javaheri as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.
Medicare pays for these items and services only when they are ordered by an eligible clinician.
What this does not show: Can order Medicare-covered services
It does not mean the clinician offers these services directly.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Compared with the same specialty in Beverly Hills and California
Billing and prescribing volume is not a quality rating.
Medicare Part B services
More Medicare Part B services than 90% of clinicians listed under Ophthalmology - Retina Specialist in California (2024, 180 clinicians with data). Median for this group: 10,375. Middle half: 3,212 to 33,038.
Too few clinicians listed under Ophthalmology - Retina Specialist in Beverly Hills have Medicare Part B data for 2024 to compare.
Medicare-allowed amount
A higher Medicare-allowed amount than 90% of clinicians listed under Ophthalmology - Retina Specialist in California (2024, 180 clinicians with data). Median for this group: $1,037,104. Middle half: $331,759 to $2,925,440.
Too few clinicians listed under Ophthalmology - Retina Specialist in Beverly Hills have Medicare Part B data for 2024 to compare.
Paid by Medicare
A higher Medicare payment amount than 90% of clinicians listed under Ophthalmology - Retina Specialist in California (2024, 180 clinicians with data). Median for this group: $805,413. Middle half: $255,362 to $2,302,429.
Too few clinicians listed under Ophthalmology - Retina Specialist in Beverly Hills have Medicare Part B data for 2024 to compare.
Medicare Part D prescriptions
Close to the middle for clinicians listed under Ophthalmology - Retina Specialist in California (2024, 188 clinicians with data). Median for this group: 378. Middle half: 171 to 746.
Too few clinicians listed under Ophthalmology - Retina Specialist in Beverly Hills have Medicare Part D data for 2024 to compare.
Part D drug cost
A higher Part D drug cost than 80% of clinicians listed under Ophthalmology - Retina Specialist in California (2024, 188 clinicians with data). Median for this group: $13,405. Middle half: $5,647 to $45,389.
Too few clinicians listed under Ophthalmology - Retina Specialist in Beverly Hills have Medicare Part D data for 2024 to compare.
5 active clinicians are listed under Ophthalmology - Retina Specialist with a practice address in Beverly Hills, CA (210 in California).
Addresses are self-reported to NPPES and may be out of date.
CMS data by year
Changes may reflect reporting, coverage or privacy limits, not changes in care quality.
-
Medicare Part B services
Medicare Part B services increased 930% from 6,019 in 2020 to 61,984 in 2024.
- 2020: 6,019
- 2021: 7,458
- 2022: 16,651
- 2023: 55,574
- 2024: 61,984
-
Medicare-allowed amount
Medicare-allowed amount increased 314% from $1,293,174 in 2020 to $5,353,947 in 2024.
- 2020: $1,293,174
- 2021: $1,879,726
- 2022: $3,279,081
- 2023: $5,074,199
- 2024: $5,353,947
-
Paid by Medicare
Paid by Medicare increased 317% from $1,013,493 in 2020 to $4,226,163 in 2024.
- 2020: $1,013,493
- 2021: $1,497,245
- 2022: $2,593,021
- 2023: $4,019,178
- 2024: $4,226,163
-
Medicare Part D prescriptions
Medicare Part D prescriptions increased 140% from 160 in 2020 to 384 in 2024.
- 2020: 160
- 2021: 186
- 2022: 240
- 2023: 373
- 2024: 384
-
30-day fills
30-day fills increased 148% from 204 in 2020 to 505 in 2024.
- 2020: 204
- 2021: 206
- 2022: 282
- 2023: 485
- 2024: 505
-
Part D drug cost
Part D drug cost increased 93% from $39,882 in 2020 to $76,925 in 2024.
- 2020: $39,882
- 2021: $54,250
- 2022: $70,394
- 2023: $108,961
- 2024: $76,925
-
Industry payments (Open Payments)
Industry payments (Open Payments) increased 472% from $23,717.23 in 2021 to $135,637.24 in 2025.
- 2021: $23,717.23
- 2022: $42,068.44
- 2023: $150,524.57
- 2024: $156,172.95
- 2025: $135,637.24
Sources: CMS Medicare Physician & Other Practitioners (2024), CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS release of October 2, 2026, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.
Text: T-MedInfo · Report an error.
Pharma & Medical Device Financial Disclosures
Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments
Program year 2025 (payments made January 1 – December 31, 2025): 166 records totaling $135,637.24.
| Manufacturer | Payment Nature | Product | Type | Amount ($) |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. |
Consulting Fee
Cash or cash equivalent
|
EYLEA HD | General | $14,100.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $7,520.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $7,520.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $7,520.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $7,050.00 |
| Apellis Pharmaceuticals, Inc. |
Compensation for serving as faculty or as a speaker for a medical education program
Cash or cash equivalent
|
Syfovre | General | $6,426.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $5,640.00 |
| Apellis Pharmaceuticals, Inc. |
Compensation for serving as faculty or as a speaker for a medical education program
Cash or cash equivalent
|
Syfovre | General | $4,914.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $4,700.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $4,700.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $4,700.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $4,700.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $4,230.00 |
| Regeneron Pharmaceuticals, Inc. |
Consulting Fee
Cash or cash equivalent
|
EYLEA | General | $3,760.00 |
| Regeneron Pharmaceuticals, Inc. |
Consulting Fee
Cash or cash equivalent
|
EYLEA | General | $3,290.00 |
| Regeneron Pharmaceuticals, Inc. |
Consulting Fee
Cash or cash equivalent
|
EYLEA | General | $2,820.00 |
| Regeneron Pharmaceuticals, Inc. |
Consulting Fee
Cash or cash equivalent
|
EYLEA | General | $2,820.00 |
| Regeneron Pharmaceuticals, Inc. |
Consulting Fee
Cash or cash equivalent
|
EYLEA HD | General | $2,820.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $2,380.29 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $2,350.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $1,880.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $1,660.67 |
| Apellis Pharmaceuticals, Inc. |
Compensation for serving as faculty or as a speaker for a medical education program
Cash or cash equivalent
|
Syfovre | General | $1,500.00 |
| Apellis Pharmaceuticals, Inc. |
Compensation for serving as faculty or as a speaker for a medical education program
Cash or cash equivalent
|
Syfovre | General | $1,500.00 |
| Apellis Pharmaceuticals, Inc. |
Compensation for serving as faculty or as a speaker for a medical education program
Cash or cash equivalent
|
Syfovre | General | $1,500.00 |
(top 25 shown)
Source: CMS Open Payments, program year 2025, released June 30, 2026.
Performed Procedures & Service Volume
CPT® is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2016–2023 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners – by Provider and Service data, 2017–2024; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
| HCPCS Code | Services | Patients | Submitted Charge | Medicare Allowed |
|---|---|---|---|---|
|
J2777
Injection, faricimab-svoa, 0.1 mg
|
45,541 | 91 | $44.00 | $34.58 |
|
92134
Imaging of retina
|
3,327 | 948 | $150.00 | $46.78 |
|
J2781
Injection, pegcetacoplan, intravitreal, 1 mg
|
2,295 | 22 | $350.00 | $146.93 |
|
67028
Injection of drug into eye
|
2,160 | 258 | $650.00 | $130.57 |
|
J0177
Injection, aflibercept hd, 1 mg
|
1,968 | 47 | $460.37 | $331.49 |
|
92014
Established patient complete exam of visual system
|
1,801 | 806 | $175.00 | $147.93 |
|
J0178
Injection, aflibercept, 1 mg
|
1,484 | 131 | $1250.00 | $827.99 |
|
92012
Established patient problem focused exam of visual system
|
644 | 234 | $150.00 | $105.55 |
|
Q5128
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg
|
565 | 41 | $500.00 | $256.47 |
|
99214
Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
|
436 | 244 | $200.00 | $147.18 |
|
92242
Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye
|
330 | 255 | $500.00 | $343.49 |
|
92201
Extended exam of the back part of the eye with retinal drawing
|
227 | 198 | $85.00 | $27.84 |
|
99204
New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
|
226 | 226 | $275.00 | $189.11 |
|
92250
Photography of the retina
|
161 | 125 | $175.00 | $42.72 |
|
92235
Exam of retinal blood vessels using a special camera after injection of a dye
|
159 | 135 | $285.00 | $197.49 |
|
92083
Exam of visual field with extended testing
|
121 | 106 | $275.00 | $72.20 |
|
92287
Imaging of front third of eye using a special camera after injection of a dye
|
114 | 83 | $285.00 | $175.02 |
|
Q5124
Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
|
100 | 13 | $500.00 | $167.14 |
|
J3490
Unclassified drugs
|
96 | 63 | $5085.42 | $3214.72 |
|
99212
Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
|
42 | 37 | $185.00 | $66.04 |
|
76512
2d ultrasound scan of eye tissue and structures
|
35 | 25 | $350.00 | $54.41 |
|
99213
Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
|
35 | 33 | $150.00 | $104.86 |
|
67145
Photocoagulation treatment to prevent detachment of retina
|
27 | 23 | $3500.00 | $283.69 |
|
92202
Extended exam of the back part of the eye with optic nerve drawing
|
23 | 23 | $75.00 | $17.38 |
|
99214
Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
|
23 | 15 | $362.94 | $107.15 |
(top 25 shown)
Source: CMS Part B by Provider and Service, 2024; services under 11 beneficiaries omitted by CMS. Privacy limits
Submitted charges are billed amounts, not a price quote for your visit.
Medicare Part D Prescribing Profile & Medications
Medicare Part D prescriptions filled, including refills, in 2024.
| Brand Name | Generic Name | Prescriptions | Day Supply | Total Cost | Patients |
|---|---|---|---|---|---|
| Prolensa | Bromfenac Sodium | 99 | 2,404 | $32,901.04 | 20 |
| Prednisolone Acetate | Prednisolone Acetate | 70 | 3,066 | $3,679.82 | 28 |
| Bromfenac Sodium | Bromfenac Sodium | 40 | 1,157 | $7,177.72 | 16 |
| Latanoprost | Latanoprost | 31 | 2,236 | $136.10 | — |
| Cyclosporine | Cyclosporine | 21 | 630 | $6,376.11 | — |
| Moxifloxacin | Moxifloxacin Hcl | 19 | 306 | $389.69 | 17 |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 19 | 570 | $2,124.06 | — |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | 697 | $496.43 | — |
| Restasis | Cyclosporine | 17 | 795 | $15,675.74 | — |
| Lumigan | Bimatoprost | 14 | 697 | $5,804.59 | — |
| Acetazolamide | Acetazolamide | 14 | 480 | $712.55 | — |
| Difluprednate | Difluprednate | 11 | 354 | $979.95 | — |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | 275 | $470.74 | — |
Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits
Specialties & License Numbers Reported to NPPES
Self-certified to NPPES: 2023-12-06NUCC Taxonomy Code: 207WX0107X
An ophthalmologist who specializes in the diagnosis and treatment of vitreoretinal diseases.
NUCC Taxonomy Code: 207W00000X
An ophthalmologist has the knowledge and professional skills needed to provide comprehensive eye and vision care. Ophthalmologists are medically trained to diagnose, monitor and medically or surgically treat all ocular and visual disorders. This includes problems affecting the eye and its component structures, the eyelids, the orbit and the visual pathways. In so doing, an ophthalmologist prescribes vision services, including glasses and contact lenses.
Additional State Medicaid & Healthcare Payer Identifiers
Medicare (PECOS) Enrollment & Ordering Eligibility
Source: CMS PECOSPRACTITIONER - OPHTHALMOLOGY
I20081021000467
CA
1052479904
Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.
Medicare Group Practice Enrollments
Source: CMS Doctors and Clinicians National Downloadable File, CMS release of October 2, 2026
Cha Medical And Surgical Group Pc
1300 N Vermont Ave, Los Angeles, CA 900276300
Phone: 8332703937
Clinicians Sharing This Practice Address or Phone
Clinicians sharing this NPPES address, phone or fax; a shared contact does not mean they work together.
Ophthalmology - Retina Specialist
Doctor of Medicine (M.D.), Doctor of Philosophy (Ph.D.)
Career & Practice History Timeline
Changes recorded in monthly NPPES data files: addresses, names, credentials, specialties and NPI status
Registered at 9735 WILSHIRE BLVD STE 219, BEVERLY HILLS, CA 902122110 (Tel: 3108586569)
Registered at 9735 WILSHIRE BLVD STE 219, BEVERLY HILLS, CA 902122110 (Tel: 3108586569)
NPI status registered as active in NPPES database
Registered at 500 N CENTRAL AVE, 4TH FLOOR, GLENDALE, CA 912033905 (Tel: 8189561010)
Registered at 500 N CENTRAL AVE, 4TH FLOOR, GLENDALE, CA 912033905 (Tel: 8189561010)
Recorded as MICHAEL JAVAHERI, M.D.
Ophthalmology (license number reported to NPPES: CA A94767)
NPI status registered as active in NPPES database
Registered at 500 N CENTRAL AVE, 4TH FLOOR, GLENDALE, CA 912033905 (Tel: 8189561010)
Registered at 500 N CENTRAL AVE, 4TH FLOOR, GLENDALE, CA 912033905 (Tel: 8189561010)
Recorded as MICHAEL JAVAHERI, M.D.
Ophthalmology (license number reported to NPPES: CA A94767)
First registered as active Individual Practitioner in NPPES Database.
NPI Administrative Meta
Other Ophthalmology - Retina Specialists in Beverly Hills
Healthcare providers in Beverly HillsMailing Address
9735 Wilshire Blvd Ste 219
Beverly Hills, CA 902122110
Phone: 3108586569